Annexon is a clinical-stage biopharmaceutical company developing a class of complement medicines designed to stop the classical complement pathway at its start, C1q, in order to bring therapies to patients suffering from serious complement-mediated autoimmune, neurodegenerative and ophthalmic disorders. Co. is developing a pipeline of product candidates designed to block the activity of C1q and the entire classical complement pathway for a range of complement-mediated diseases. Co.'s pipeline includes three clinical-stage assets across three therapeutic franchises: autoimmune, neurodegenration and ophtamology. Co. its developing its primary candidate, ANX005. We show 11 historical shares outstanding datapoints in our ANNX shares outstanding history coverage, used to compute ANNX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ANNX market cap history over the course of time is important for investors
interested in comparing ANNX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ANNX versus a peer is one thing; comparing
ANNX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ANNX can fluctuate over the course of history.
With this page we aim to empower investors researching ANNX by allowing them to research the ANNX market cap history. |
Free ANNX Email Alerts:
Video: The Importance of Market Cap
